PRABio · Protein Ruler to Create Affordable Biosensor Diagnosis for the Many

Ovarian cancer is the most common malignancy of the female reproductive system worldwide, and the leading cause of death fromgynecological cancer. However, if diagnosed during the early stages, patients have a good prognosis, at around 90% 5-year survivalrate. Despite its lethality, there are currently no effective simple tests for diagnosis nor population-based screening techniques forovarian cancer. Emerging tests detecting cancer biomarkers have the potential for greatest impact for surveillance and earlydetection, such as the FDA approved CA125 and HE4 biomarkers. Importantly, because the levels of these biomarkers are not thesame among all healthy females and increase with age, these tests should be quantitative. Current quantitative diagnostic tests forCA125 and HE4 detection are expensive, require high-cost infrastructures and trained professionals. Therefore, there is an urgentneed for developing cheap, reliable, easy-to-use quantitative tests for ovarian cancer biomarkers. In this project, ground-breaking innovating research will give rise to novel technology, enabling the detection of cancer biomarkers in a manner that is quantitative, and yetsimple, portable and cheap.